


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:57Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406345" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406345</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneul</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406345</article-id><article-id pub-id-type="pmcid-ver">PMC12406345.1</article-id><article-id pub-id-type="pmcaid">12406345</article-id><article-id pub-id-type="pmcaiid">12406345</article-id><article-id pub-id-type="pmid">40898163</article-id><article-id pub-id-type="doi">10.1186/s12883-025-04394-z</article-id><article-id pub-id-type="publisher-id">4394</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>The role of Atogepant in migraine prevention: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ladhwani</surname><given-names initials="NK">Naresh Kumar</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="P">Priya</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lal</surname><given-names initials="R">Rohan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="AM">Aresha Masood</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bai</surname><given-names initials="S">Sheela</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ahmed</surname><given-names initials="GU">Ghazi Uddin</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zameer</surname><given-names initials="R">Rimsha</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shaikh</surname><given-names initials="VF">Varisha Fatima</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hyder</surname><given-names initials="A">Arsalan</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ali</surname><given-names initials="S">Sikander</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beg</surname><given-names initials="MH">Muhammad Hamza</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Adeeb</surname><given-names initials="M">Maheen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Tesfaye</surname><given-names initials="M">Mahir</given-names></name><address><email>Mahirtesfaye8@gmail.com</email></address><xref ref-type="aff" rid="Aff8">8</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01h85hm56</institution-id><institution-id institution-id-type="GRID">grid.412080.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9363 9292</institution-id><institution>Dow University of Health Sciences, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024m1xa82</institution-id><institution-id institution-id-type="ISNI">0000 0004 1779 4388</institution-id><institution>Peoples University of Medical Health and Sciences for Women, </institution></institution-wrap>Nawabshah, Pakistan </aff><aff id="Aff3"><label>3</label>Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/010pmyd80</institution-id><institution-id institution-id-type="GRID">grid.415944.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0606 9084</institution-id><institution>Jinnah Sindh Medical University, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/015jxh185</institution-id><institution-id institution-id-type="GRID">grid.411467.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 8689 0294</institution-id><institution>Liaquat University of Medical and Health Sciences, </institution></institution-wrap>Jamshoro, Pakistan </aff><aff id="Aff6"><label>6</label>PNS Shifa Hospital, Karachi, Pakistan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01h85hm56</institution-id><institution-id institution-id-type="GRID">grid.412080.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9363 9292</institution-id><institution>Dow Medical College, </institution></institution-wrap>Karachi, Pakistan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038b8e254</institution-id><institution-id institution-id-type="GRID">grid.7123.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1250 5688</institution-id><institution>Addis Ababa University, </institution></institution-wrap>Addis Ababa, Ethiopia </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478179</issue-id><elocation-id>375</elocation-id><history><date date-type="received"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12883_2025_Article_4394.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Atogepant is a CGRP receptor antagonist used in prevention of migraine. This study assesses the safety and efficacy of this drug in management of migraine headaches.</p></sec><sec><title>Methods</title><p id="Par2">PubMed, Scopus, Web of Science, and Cochrane CENTRAL were searched until March 24, 2025. Outcomes assessed included monthly migraine and headache day change from baseline at 12 weeks, &#8805;&#8201;50% reduction in monthly migraine days (MMD), acute medication use days at 12 weeks, treatment-emergent adverse events (TEAE), score on Role Function-Restrictive domain of MSQ at 12 weeks, score on daily activity performance and physical impairment domains of AIM-D at 12 weeks. Subgroup analysis was performed based on different doses of atogepant.</p></sec><sec><title>Results</title><p id="Par3">Six RCTs comprising of 4052 patients were included. Atogepant showed significant improvement in patients with migraine in terms of MMD over 12 weeks at all doses, 10&#160;mg, 30&#160;mg, and 60&#160;mg. Moreover, it also reduced monthly headache days, had 50% reduction in MMD, and reduced days requiring acute medication use. Atogepant was shown to increase the risk of TEAE, particularly gastrointestinal (GI) side effect including constipation and nausea, however, occurrence of other side effects with atogepant use was insignificant.</p></sec><sec><title>Conclusion</title><p id="Par4">Atogepant is a highly effective CGRP antagonist for migraine prevention, however, it is associated with increased incidence of GI side effects. Further studies are needed to comprehensively investigate the relationship between atogepant dosage and migraine improvement and safety profile.</p></sec><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1186/s12883-025-04394-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Atogepant</kwd><kwd>CGRP antagonist</kwd><kwd>Chronic migraine</kwd><kwd>Episodic migraine</kwd><kwd>Meta-analysis</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Migraine is a commonly occurring neurological condition characterized by recurrent severe headaches [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. These headaches are pulsatile and throbbing in nature usually affecting one side of the head. Migraine is often associated with nausea, vomiting, mood changes, fatigue [<xref ref-type="bibr" rid="CR1">1</xref>]. Moreover, these patients also experience photophobia, phonophobia, and sensitivity to smell [<xref ref-type="bibr" rid="CR1">1</xref>]. In some individuals, migraine may be preceded by an aura, which are reversible neurological manifestations which in many causes can be highly disabling [<xref ref-type="bibr" rid="CR3">3</xref>]. Auras include visual disturbances such as flashing lights, loss of vision, paresthesias, unilateral body or facial weakness, and speaking difficulty [<xref ref-type="bibr" rid="CR3">3</xref>]. </p><p id="Par6">As of 2019, migraine has been found to affect around 1.1 billion people worldwide, with highest prevalence in Europe, particularly Belgium and Italy [<xref ref-type="bibr" rid="CR2">2</xref>]. From 1990 to 2019, the prevalence of migraine has substantially increased from 721.9 million in 1990, to 1.1 billion in 2019 [<xref ref-type="bibr" rid="CR2">2</xref>]. Statistics have shown that migraine affects women more than men and typically occurs in young adults [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Risk factors and triggers of migraine include hormonal fluctuations in women, alcohol consumption, stress, strong sensory stimuli such as bright flashing lights or strong odors, physical exertion, changes in weather, medication including oral contraceptive pills (OCPs) and vasodilators such as nitroglycerine etc [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. </p><p id="Par7">The pathophysiology of migraine is complex and involves neuronal hyperexcitability, cortical spreading depression, and trigeminovascular system activation. Key features associated with chronic migraine are central sensitization and altered pain modulation in the brainstem [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Dysregulation in CGRP signaling plays a pivotal role, particularly through pro-nociceptive and vasodilatory actions. This mechanism highlights that blockade of CGRP may predispose to or worsen cardiovascular conditions. CGRP levels have been found to be elevated during migraine attacks and they normalize after treatment [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Pannexin channels and neuroinflammation are also proposed mechanism, however, they are more relevant in migraine with aura rather than with chronic migraine [<xref ref-type="bibr" rid="CR10">10</xref>]. </p><p id="Par8">The first step in management of migraine involves lifestyle modifications which should be focused on avoiding triggers [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Pharmacological approach of migraine involves two plans: abortive treatment and prophylactic or preventative treatment. Medications used for acute migraine include acetaminophen, non-steroidal anti-inflammatory drugs (NSAIDs), antiemetics and triptans, for example sumatriptan [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Prophylactic treatment includes beta-blockers, such as propranolol, antidepressants, like tricyclic antidepressants (TCAs), anticonvulsants, including valproate and topiramate, calcium channel blockers, CGRP inhibitors, and botulinum toxin [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. </p><p id="Par9">Chronic migraine, headaches for 15 or more days per month for more than three months, is associated with significant impairment and decreased quality of life. One of the pathophysiological mechanisms of chronic migraine, as mentioned above, is closely attributed to persistent CGRP signaling, thus, preventative therapies are crucial to reduce frequency of attacks and progression. Previous preventative therapies such as beta-blockers, anticonvulsants, and tricyclics have showed variable efficacy, prompting development of targeted therapies such as CGRP receptor antagonists and monoclonal antibodies. In addition to small molecule antagonists like atogepant, monoclonal antibodies against CGRP like erenumab, fremanezumab etc., have also showed improvement in migraine prevention and are thus important alternatives [<xref ref-type="bibr" rid="CR13">13</xref>]. </p><p id="Par10">Atogepant is a new drug designed for prevention of migraine via inhibition of CGRP [<xref ref-type="bibr" rid="CR14">14</xref>]. Compared to other drugs in this class, atogepant has been found to have a significant effect in migraine reduction with a better safety profile [<xref ref-type="bibr" rid="CR14">14</xref>]. Previous meta-analyses on this topic have investigated efficacy of atogepant, however, limited number of trials were included with sole focus on episodic migraine. Moreover, comparative analysis based on dosages of atogepant also has limited literature. This updated meta-analysis and systematic review aims bridge those gaps and gathers and analyzes data from randomized controlled trials (RCTs) to comprehensively explore the safety and effectiveness of atogepant at different dosages in episodic and chronic migraine prevention.</p></sec><sec id="Sec2"><title>Methods</title><p id="Par11">The Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines and the Risk of Bias in Systematic Reviews and Assessment of Multiple Systematic Reviews (AMSTAR) 2 were both followed while conducting this meta-analysis [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. </p><sec id="Sec3"><title>Search strategy and screening</title><p id="Par12">PubMed, Scopus, Web of Science, and Cochrane CENTRAL were looked up from inception through March 24, 2025, by two independent reviewers, Table S1. Studies were extracted based on abstracts and titles. A full-text appraisal was sought when required. The search string used for literature search was: [(&#8220;atogepant&#8221; OR &#8220;CGRP antagonists&#8221; OR &#8220;calcitonin gene-related peptide antagonists&#8221;) AND (&#8220;migraine disorder&#8221; OR &#8220;headache disorders&#8221; OR &#8220;chronic migraine&#8221; OR &#8220;episodic migraine&#8221;)]. To ensure extraction of largest number of relevant studies, filters were deferred, and references from included studies were also searched.</p><p id="Par13">The search strategy identified RCTs comparing atogepant with placebo or standard care in patients diagnosed with migraine. We aimed to include all RCTs, whether open-label or double-blinded, to provide a comprehensive evaluation of atogepant&#8217;s safety and efficacy profile in migraine prevention.</p><p id="Par14">Screening of titles and abstracts was carried out by two independent reviewers and discrepancies were resolved by consensus from a third reviewer. Full-text screening was performed on studies that met the inclusion criteria, and any conflicts were further discussed to reach a final decision.</p></sec><sec id="Sec4"><title>Study selection and quality assessment</title><p id="Par15">The following inclusion criteria was applied: (1) randomized controlled trials (RCTs), non-randomized controlled trials, and cohort or analysis that determined the safety and efficacy of atogepant versus placebo or standard care, (2) reported either Monthly Migraine Days (MMD) change from baseline, &#8805;&#8201;50% Reduction in MMD, days at 12 weeks with acute medication use, Treatment-emergent adverse events (TEAE), score on function-restrictive domain of migraine specific quality of life questionnaire (MSQ) at 12 weeks, or score on daily activity performance or physical impairment domain of activity impairment in migraine diary (AIM-D) at 12 weeks (3) included patients with migraine or history of migraine (4) Articles with English titles and abstracts. All review articles, case reports, case series, editorials, commentaries and animal-based studies were excluded from this meta-analysis. A third investigator was consulted if any disagreement regarding study selection was encountered. All articles were uploaded to Endnote Reference Library (Version X7.5; Clarivate Analytics, Philadelphia, Pennsylvania) software for duplicates removal.</p><p id="Par16">Two reviewers independently extracted the study characteristics from the selected studies, including patient demographics, summary events, number of events, sample sizes, and treatment type. Summary events for outcomes of interest and mean difference (MD) with standard deviation (SD) from the baseline were also extracted. The quality assessment and risk of bias of the included studies was conducted through the Cochrane risk of bias tool for RCT (Table S2 and Figs. <xref rid="Fig1" ref-type="fig">1</xref> and <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR17">17</xref>]. <fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Risk of bias graph</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig1_HTML.jpg"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Risk of bias summary</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par17">RevMan (version 5.4.1; Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration) was used for the meta-analysis. The outcomes of interest were provided as MDs with 95% confidence intervals (Cis) and were pooled using an inverse variance weighted random-effects model. When the mean was not available, median was used for analysis. Difference in means between the baseline and the post-treatment measurements were calculated where change from the baseline was not reported. The standard deviation (SD) was derived from the baseline and the follow-up by assuming their correlations were 0.5. Leave-one-out and subgroup analyses were performed with different controls where heterogeneity was present. The Higgins I [<xref ref-type="bibr" rid="CR2">2</xref>] was utilized to assess heterogeneity between trials. A 25&#8211;50% number was considered low, 50&#8211;75% moderate, and &gt;&#8201;75% serious. A P-value less than 0.05 was considered significant in all cases.</p></sec></sec><sec id="Sec6"><title>Results</title><sec id="Sec7"><title>Search results and baseline characteristics</title><p id="Par18">The PRISMA flow chart summarizes the search and study selection process (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). The initial search yielded a total of 448 results. After screening and duplicate removal, 257 articles were assessed for eligibility, and 24 were selected for retrieval and eligibility assessment. With further exclusion 6 RCTs with a total of 4052 participants, were shortlisted for data extraction [<xref ref-type="bibr" rid="CR18">18</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Of the 4052 total participants 2867 were randomized to the atogepant group, while 1185 were randomized into the placebo group. Table <xref rid="Tab1" ref-type="table">1</xref> shows the study characteristics and Table <xref rid="Tab2" ref-type="table">2</xref> shows the baseline characteristics of the included studies.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Prisma flow chart</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig3_HTML.jpg"/></fig><table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>General characteristics of included RCTs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="left" rowspan="2" colspan="1">Dose</th><th align="left" rowspan="2" colspan="1">Total Sample</th><th align="left" colspan="2" rowspan="1">Sample size</th><th align="left" rowspan="2" colspan="1">Country</th><th align="left" rowspan="2" colspan="1">Follow-up Duration</th><th align="left" rowspan="2" colspan="1">Patient Category</th><th align="left" rowspan="2" colspan="1">Primary Outcome</th></tr><tr><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1"> Ailani et al. 2021</td><td align="left" colspan="1" rowspan="1">10 mg Once Daily</td><td char="." align="char" rowspan="3" colspan="1">902</td><td char="." align="char" colspan="1" rowspan="1">221</td><td char="." align="char" rowspan="3" colspan="1">222</td><td align="left" rowspan="3" colspan="1">N/A</td><td align="left" rowspan="3" colspan="1">12 weeks</td><td align="left" rowspan="3" colspan="1">Episodic Migraine</td><td align="left" rowspan="3" colspan="1">Change from baseline in Monthly Migraine Days</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">228</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">231</td></tr><tr><td align="left" colspan="1" rowspan="1">Allergan et al. 2021</td><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">739</td><td char="." align="char" colspan="1" rowspan="1">543</td><td char="." align="char" colspan="1" rowspan="1">196</td><td align="left" colspan="1" rowspan="1">USA</td><td align="left" colspan="1" rowspan="1">52 weeks</td><td align="left" colspan="1" rowspan="1">Episodic Migraine</td><td align="left" colspan="1" rowspan="1">Treatment Emergent Adverse Event</td></tr><tr><td align="left" rowspan="5" colspan="1"> Goadsby et al. 2020</td><td align="left" colspan="1" rowspan="1">10 mg Once Daily</td><td char="." align="char" rowspan="5" colspan="1">825</td><td char="." align="char" colspan="1" rowspan="1">93</td><td char="." align="char" rowspan="5" colspan="1">186</td><td align="left" rowspan="5" colspan="1">USA</td><td align="left" rowspan="5" colspan="1">12 weeks</td><td align="left" rowspan="5" colspan="1">Episodic Migraine</td><td align="left" rowspan="5" colspan="1">Change from baseline in Monthly Migraine Days</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">183</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">186</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" colspan="1" rowspan="1">86</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Twice Daily</td><td char="." align="char" colspan="1" rowspan="1">91</td></tr><tr><td align="left" rowspan="2" colspan="1"> Goadsby et al. 2024</td><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" rowspan="2" colspan="1">500</td><td char="." align="char" colspan="1" rowspan="1">161</td><td char="." align="char" rowspan="2" colspan="1">169</td><td align="left" rowspan="2" colspan="1">N/A</td><td align="left" rowspan="2" colspan="1">12 weeks</td><td align="left" rowspan="2" colspan="1">Chronic Migraine</td><td align="left" rowspan="2" colspan="1">Change from baseline in Monthly Migraine Days</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">170</td></tr><tr><td align="left" rowspan="2" colspan="1"> Pozo-Rosich et al. 2023</td><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" rowspan="2" colspan="1">773</td><td char="." align="char" colspan="1" rowspan="1">257</td><td char="." align="char" rowspan="2" colspan="1">255</td><td align="left" rowspan="2" colspan="1">USA/Canada</td><td align="left" rowspan="2" colspan="1">12 weeks</td><td align="left" rowspan="2" colspan="1">Chronic Migraine</td><td align="left" rowspan="2" colspan="1">Change from baseline in Monthly Migraine Days</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">261</td></tr><tr><td align="left" colspan="1" rowspan="1"> Tassorelli et al. 2024</td><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">313</td><td char="." align="char" colspan="1" rowspan="1">156</td><td char="." align="char" colspan="1" rowspan="1">157</td><td align="left" colspan="1" rowspan="1">North America/Europe</td><td align="left" colspan="1" rowspan="1">12 weeks</td><td align="left" colspan="1" rowspan="1">Episodic Migraine</td><td align="left" colspan="1" rowspan="1">Change from baseline in Monthly Migraine Days</td></tr></tbody></table><table-wrap-foot><p>*All the included studies are Randomized Controlled Trials (RCTs)</p><p>N/A: Not Applicable</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Patient baseline characteristics table</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Study</th><th align="left" rowspan="2" colspan="1">Dose</th><th align="left" rowspan="2" colspan="1">Total Sample</th><th align="left" colspan="2" rowspan="1">Sample Size</th><th align="left" colspan="2" rowspan="1">Mean Age</th><th align="left" colspan="2" rowspan="1">Sex</th><th align="left" colspan="2" rowspan="1">Weight (Kg)</th><th align="left" colspan="2" rowspan="1">Height (cm)</th><th align="left" colspan="2" rowspan="1">BMI</th><th align="left" colspan="2" rowspan="1">MMDs baseline</th><th align="left" colspan="2" rowspan="1">MHDs baseline</th><th align="left" colspan="2" rowspan="1">Acute medicine use days baseline</th></tr><tr><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Male</th><th align="left" colspan="1" rowspan="1">Female</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th><th align="left" colspan="1" rowspan="1">Atogepant</th><th align="left" colspan="1" rowspan="1">Placebo</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1"> Ailani et al. 2021</td><td align="left" colspan="1" rowspan="1">10 mg Once Daily</td><td char="." align="char" rowspan="3" colspan="1">902</td><td char="." align="char" colspan="1" rowspan="1">221</td><td char="." align="char" rowspan="3" colspan="1">222</td><td char="." align="char" colspan="1" rowspan="1">41.4(12.0)</td><td char="." align="char" rowspan="3" colspan="1">40.3(12.8)</td><td char="." align="char" rowspan="3" colspan="1">101</td><td char="." align="char" rowspan="3" colspan="1">801</td><td align="left" rowspan="3" colspan="1">&#8722;</td><td align="left" rowspan="3" colspan="1">&#8722;</td><td align="left" rowspan="3" colspan="1">&#8722;</td><td align="left" rowspan="3" colspan="1">&#8722;</td><td align="left" rowspan="3" colspan="1">30.6(7.8)</td><td align="left" rowspan="3" colspan="1">30.8(8.7)</td><td align="left" colspan="1" rowspan="1">7.5(2.5)</td><td align="left" rowspan="3" colspan="1">7.5(2.4)</td><td align="left" colspan="1" rowspan="1">8.4(2.8)</td><td align="left" rowspan="3" colspan="1">8.4(2.6)</td><td align="left" colspan="1" rowspan="1">6.6(3.0)</td><td align="left" rowspan="3" colspan="1">6.5(3.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">228</td><td char="." align="char" colspan="1" rowspan="1">42.1(11.7)</td><td align="left" colspan="1" rowspan="1">7.9(2.3)</td><td align="left" colspan="1" rowspan="1">8.8(2.6)</td><td align="left" colspan="1" rowspan="1">6.7(3.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">231</td><td char="." align="char" colspan="1" rowspan="1">42.5(12.4)</td><td align="left" colspan="1" rowspan="1">7.8(2.3)</td><td align="left" colspan="1" rowspan="1">9.0(2.6)</td><td align="left" colspan="1" rowspan="1">6.9 (3.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Allergan et al. 2021</td><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">739</td><td char="." align="char" colspan="1" rowspan="1">543</td><td char="." align="char" colspan="1" rowspan="1">196</td><td char="." align="char" colspan="1" rowspan="1">41.1(12.09)</td><td char="." align="char" colspan="1" rowspan="1">42.5(12.03)</td><td char="." align="char" colspan="1" rowspan="1">88</td><td char="." align="char" colspan="1" rowspan="1">651</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">&#8722;</td></tr><tr><td align="left" rowspan="5" colspan="1"> Goadsby et al. 2020</td><td align="left" colspan="1" rowspan="1">10 mg Once Daily</td><td char="." align="char" rowspan="5" colspan="1">825</td><td char="." align="char" colspan="1" rowspan="1">93</td><td char="." align="char" rowspan="5" colspan="1">186</td><td char="." align="char" colspan="1" rowspan="1">39.4 (12.4)</td><td char="." align="char" rowspan="5" colspan="1">40.5(11.7)</td><td char="." align="char" rowspan="5" colspan="1">111</td><td char="." align="char" rowspan="5" colspan="1">714</td><td align="left" rowspan="5" colspan="1">&#8722;</td><td align="left" rowspan="5" colspan="1">&#8722;</td><td align="left" rowspan="5" colspan="1">&#8722;</td><td align="left" rowspan="5" colspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">29.9 (7.3)</td><td align="left" rowspan="5" colspan="1">30.4(7.6)</td><td align="left" colspan="1" rowspan="1">7.6 (2.5)</td><td align="left" rowspan="5" colspan="1">7.8 (2.5)</td><td align="left" colspan="1" rowspan="1">8.9 (2.7)</td><td align="left" rowspan="5" colspan="1">9.1 (2.7)</td><td align="left" colspan="1" rowspan="1">6.2 (3.3)</td><td align="left" rowspan="5" colspan="1">6.6 (3.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">183</td><td char="." align="char" colspan="1" rowspan="1">41.0 (13.6)</td><td align="left" colspan="1" rowspan="1">30.0 (7.1)</td><td align="left" colspan="1" rowspan="1">7.6 (2.4)</td><td align="left" colspan="1" rowspan="1">8.7 (2.5)</td><td align="left" colspan="1" rowspan="1">6.6 (3.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">186</td><td char="." align="char" colspan="1" rowspan="1">40.4 (11.7)</td><td align="left" colspan="1" rowspan="1">30.0 (7.8)</td><td align="left" colspan="1" rowspan="1">7.7 (2.6)</td><td align="left" colspan="1" rowspan="1">8.9 (2.8)</td><td align="left" colspan="1" rowspan="1">6.8 (3.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" colspan="1" rowspan="1">86</td><td char="." align="char" colspan="1" rowspan="1">38.5 (11.2)</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">7.4 (2.4)</td><td align="left" colspan="1" rowspan="1">8.7 (2.7)</td><td align="left" colspan="1" rowspan="1">6.2 (3.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Twice Daily</td><td char="." align="char" colspan="1" rowspan="1">91</td><td char="." align="char" colspan="1" rowspan="1">39.7 (11.9)</td><td align="left" colspan="1" rowspan="1">7.6 (2.6)</td><td align="left" colspan="1" rowspan="1">8.8 (3.1)</td><td align="left" colspan="1" rowspan="1">6.4 (3.4)</td></tr><tr><td align="left" rowspan="2" colspan="1"> Goadsby et al. 2024</td><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" rowspan="2" colspan="1">500</td><td char="." align="char" colspan="1" rowspan="1">161</td><td char="." align="char" rowspan="2" colspan="1">169</td><td char="." align="char" colspan="1" rowspan="1">42.6(11.9)</td><td char="." align="char" rowspan="2" colspan="1">42.0(12.4)</td><td char="." align="char" rowspan="2" colspan="1">96</td><td char="." align="char" rowspan="2" colspan="1">677</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">18.6 (5.1)</td><td align="left" rowspan="2" colspan="1">18.9 (4.8)</td><td align="left" colspan="1" rowspan="1">21.1 (4.1)</td><td align="left" rowspan="2" colspan="1">21.4 (4.1)</td><td align="left" colspan="1" rowspan="1">14.5 (7.2)</td><td align="left" rowspan="2" colspan="1">15.4 (7.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">170</td><td char="." align="char" colspan="1" rowspan="1">41.7(12.3)</td><td align="left" colspan="1" rowspan="1">19.2 (5.3)</td><td align="left" colspan="1" rowspan="1">21.5 (4.3)</td><td align="left" colspan="1" rowspan="1">15.5 (7.4)</td></tr><tr><td align="left" rowspan="2" colspan="1">Pozo- Rosich et al. 2023</td><td align="left" colspan="1" rowspan="1">30 mg Twice Daily</td><td char="." align="char" rowspan="2" colspan="1">773</td><td char="." align="char" colspan="1" rowspan="1">257</td><td char="." align="char" rowspan="2" colspan="1">255</td><td char="." align="char" colspan="1" rowspan="1">42.6 (11.9)</td><td char="." align="char" rowspan="2" colspan="1">42.0 (12.4)</td><td char="." align="char" rowspan="2" colspan="1">115</td><td char="." align="char" rowspan="2" colspan="1">663</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" rowspan="2" colspan="1">&#8722;</td><td align="left" colspan="1" rowspan="1">164.6 (8.3)</td><td align="left" rowspan="2" colspan="1">164.1 (7.7)</td><td align="left" colspan="1" rowspan="1">26.2 (6.7)</td><td align="left" rowspan="2" colspan="1">25.5 (6.0)</td><td align="left" colspan="1" rowspan="1">18.6 (5.1)</td><td align="left" rowspan="2" colspan="1">18.9 (4.8)</td><td align="left" colspan="1" rowspan="1">21.1 (4.1)</td><td align="left" rowspan="2" colspan="1">21.4 (4.1)</td><td align="left" colspan="1" rowspan="1">14.5 (7.2)</td><td align="left" rowspan="2" colspan="1">15.4 (7.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">261</td><td char="." align="char" colspan="1" rowspan="1">41.7 (12.3)</td><td align="left" colspan="1" rowspan="1">165.0 (8.5)</td><td align="left" colspan="1" rowspan="1">25.0 (5.5)</td><td align="left" colspan="1" rowspan="1">19.2 (5.3)</td><td align="left" colspan="1" rowspan="1">21.5 (4.3)</td><td align="left" colspan="1" rowspan="1">15.5 (7.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Tassorelli et al. 2024</td><td align="left" colspan="1" rowspan="1">60 mg Once Daily</td><td char="." align="char" colspan="1" rowspan="1">313</td><td char="." align="char" colspan="1" rowspan="1">156</td><td char="." align="char" colspan="1" rowspan="1">157</td><td char="." align="char" colspan="1" rowspan="1">40.9 (10.7)</td><td char="." align="char" colspan="1" rowspan="1">43.4 (10.3)</td><td char="." align="char" colspan="1" rowspan="1">33</td><td char="." align="char" colspan="1" rowspan="1">280</td><td align="left" colspan="1" rowspan="1">71.7 (14.8)</td><td align="left" colspan="1" rowspan="1">74.0 (16.1)</td><td align="left" colspan="1" rowspan="1">167.3 (7.9)</td><td align="left" colspan="1" rowspan="1">167.9 (7.1)</td><td align="left" colspan="1" rowspan="1">25.6 (4.9)</td><td align="left" colspan="1" rowspan="1">26.2 (5.2)</td><td align="left" colspan="1" rowspan="1">9.1 (2.3)</td><td align="left" colspan="1" rowspan="1">9.3 (2.4)</td><td align="left" colspan="1" rowspan="1">9.9 (2.4)</td><td align="left" colspan="1" rowspan="1">10.1 (2.4)</td><td align="left" colspan="1" rowspan="1">7.5 (2.9)</td><td align="left" colspan="1" rowspan="1">7.7 (3.3)</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec8"><title>Outcomes</title><sec id="Sec9"><title>Monthly migraine days change from baseline at 12 weeks</title><p id="Par19">A total of 5 studies reported change from baseline in monthly migraine days (MMD) at 12 weeks. Data analyzed included different doses mentioned in each of the studies to provide a comprehensive conclusion. Analysis showed a significant difference between atogepant and placebo group (MD: &#8722;1.31, 95% CI [&#8722;1.53, &#8722;1.10], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;97%), Fig. <xref rid="Fig4" ref-type="fig">4</xref>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Change from baseline in monthly migraine days at 12 weeks</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig4_HTML.jpg"/></fig></p><p id="Par20">A subgroup analysis was also performed for this outcome based on different dosages of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained significant, however, no change in heterogeneity (I&#178; remained 97% after subgrouping) was seen (MD: &#8722;1.31, 95% CI [&#8722;1.53, &#8722;1.10], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;97%), Supplemental Figure S1. A subgroup analysis performed on episodic and chronic migraine also showed a significant difference (MD: &#8722;1.54, 95% CI [&#8722;1.69, &#8722;1.38], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;91%), Supplemental Figure S1 A.</p></sec><sec id="Sec10"><title>Change from baseline in monthly headache days at 12 weeks</title><p id="Par21">Five studies reported changes in monthly headache days (MHD) from baseline at 12 weeks. from all studies, including different doses, were analyzed to provide a comprehensive conclusion. Analysis showed a significant difference between atogepant and placebo group (MD: &#8722;1.54, 95% CI [&#8722;1.69, &#8722;1.38], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;91%), Fig. <xref rid="Fig5" ref-type="fig">5</xref>. In order to reduce heterogeneity, leave one out analysis was performed and excluding data from Ailani et al. 2021 showed that the heterogeneity decreased from 91 to 0%, Supplemental Figure S2. Elimination of other studies did not change heterogeneity significantly.<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Change from baseline in monthly headache days at 12 weeks</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig5_HTML.jpg"/></fig></p><p id="Par22">Subgroup analysis was conducted based on different doses of atogepant, including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained significant, and no change in heterogeneity (I&#178; remained 91% after subgrouping) was observed (MD: &#8722;1.54, 95% CI [&#8722;1.69, &#8722;1.38], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;91%), Supplemental Figure S3. A subgroup analysis on type of migraine was also performed including episodic and chronic migraine which revealed a similar result (MD: &#8722;1.54, 95% CI [&#8722;1.69, &#8722;1.38], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;91%), Supplemental Figure S3A.</p></sec><sec id="Sec11"><title>&#8805;&#8201;50% reduction in monthly migraine days</title><p id="Par23">Five studies reported&#8201;&#8805;&#8201;50% Reduction in MMD. Analyzed data included different dosages mentioned in each study. A significant difference between atogepant and placebo group was recorded (MD: 1.65, 95% CI [1.48, 1.84], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;57%), Fig. <xref rid="Fig6" ref-type="fig">6</xref>. To reduce heterogeneity, leave one out analysis was performed and excluding data from Goadsby et al. 2020 showed a reduction in heterogeneity from 57 to 38%, Supplemental Figure S4. Excluding data from other studies did not significantly impact the heterogeneity.<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>&#8805;50% Reduction in monthly migraine days</p></caption><graphic id="MO6" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig6_HTML.jpg"/></fig></p><p id="Par24">Subgroup analysis based on different doses was performed. The results remained significant and no change in heterogeneity (I&#178; remained 57% after subgrouping) was seen (MD: 1.65, 95% CI [1.48, 1.84], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0001, I<sup>2</sup>&#8201;=&#8201;57%), Supplemental Figure S5. Subgroup analysis on type of migraine revealed similar results (MD: 1.65, 95% CI [1.48, 1.84], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0001, I<sup>2</sup>&#8201;=&#8201;57%), Supplemental Figure S5A.</p></sec><sec id="Sec12"><title>Acute medication use days at 12 weeks</title><p id="Par25">A total of 4 studies reported acute medication, included triptans, ergot derivatives, opioids, analgesics, NSAIDs, and antiemetic agents, use days at 12 weeks as an outcome. Analysis showed a significant difference between atogepant and placebo group (MD: &#8722;1.62, 95% CI [&#8722;1.95, &#8722;1.29], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;35%), Fig. <xref rid="Fig7" ref-type="fig">7</xref>.<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Acute Medication Use Days at 12 weeks</p></caption><graphic id="MO7" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig7_HTML.jpg"/></fig></p><p id="Par26">A subgroup analysis was also performed for this outcome based on different doses of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained significant, however, no change in heterogeneity (I&#178; remained 35% after subgrouping) was seen (MD: &#8722;1.62, 95% CI [&#8722;1.95, &#8722;1.29], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;35%), Supplemental Figure S6. Subgroup analysis on type of migraine, including episodic and chronic migraine also yielded significant results (MD: &#8722;1.68, 95% CI [&#8722;2.03, &#8722;1.32], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;44%), Supplemental Figure S6A.</p></sec><sec id="Sec13"><title>Any Treatment-emergent adverse events</title><p id="Par27">Six studies reported any treatment-emergent adverse events (TEAEs) as an outcome. Analysis comprised of different doses recorded in each of the studies. A significant difference between atogepant and placebo group was seen (MD: 1.10, 95% CI [1.00, 1.20], <italic toggle="yes">P</italic>&#8201;=&#8201;0.05, I<sup>2</sup>&#8201;=&#8201;75%), Fig. <xref rid="Fig8" ref-type="fig">8</xref>.<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Any TEAEs</p></caption><graphic id="MO8" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig8_HTML.jpg"/></fig></p><p id="Par28">Subgroup analysis was done based on different doses of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. No change in results was noticed (MD: 1.10, 95% CI [1.00, 1.20], <italic toggle="yes">P</italic>&#8201;=&#8201;0.05, I<sup>2</sup>&#8201;=&#8201;75%), Supplemental Figure S7. A subgroup analysis on type of migraine showed similar results (MD: 1.10, 95% CI [1.00, 1.20], <italic toggle="yes">P</italic>&#8201;=&#8201;0.05, I<sup>2</sup>&#8201;=&#8201;75%), Supplemental Figure S7A.</p></sec><sec id="Sec14"><title>Any treatment-related TEAEs</title><p id="Par29">A total of 5 studies reported any treatment-related TEAEs as an outcome. Analysis included different dosages in each of the studies for a comprehensive comparison. Analysis showed a significant difference between atogepant and placebo group (MD: 1.53, 95% CI [1.35, 1.74], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;0%), Fig. <xref rid="Fig9" ref-type="fig">9</xref>.<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Any treatment-related TEAEs</p></caption><graphic id="MO9" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig9_HTML.jpg"/></fig></p><p id="Par30">Subgroup analysis based on different doses showed no changes in the results (MD: 1.53, 95% CI [1.35, 1.74], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;0%), Supplemental Figure S8. Subgroup analysis on type of migraine, episodic and chronic, revealed similar results (MD: 1.53, 95% CI [1.35, 1.74], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;0%), Supplemental Figure S8A.</p></sec><sec id="Sec15"><title>Serious TEAEs</title><p id="Par31">Six studies reported serious TEAEs as an outcome. Analysis included different doses listed in each of the studies for a comprehensive conclusion. No significant difference between atogepant and placebo group was seen (MD: 1.13, 95% CI [0.77, 1.66], <italic toggle="yes">P</italic>&#8201;=&#8201;0.54, I<sup>2</sup>&#8201;=&#8201;0%), Fig. <xref rid="Fig10" ref-type="fig">10</xref>.<fig id="Fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>Serious TEAEs</p></caption><graphic id="MO10" position="float" orientation="portrait" xlink:href="12883_2025_4394_Fig10_HTML.jpg"/></fig></p><p id="Par32">A subgroup analysis was performed based on different doses of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained insignificant and no change in heterogeneity (I&#178; remained 0% after subgrouping) was seen (MD: 1.13, 95% CI [0.77, 1.66], <italic toggle="yes">P</italic>&#8201;=&#8201;0.54, I<sup>2</sup>&#8201;=&#8201;0%), Supplemental Figure S9. Subgroup analysis on type of migraine had similar results (MD: 1.13, 95% CI [0.77, 1.66], <italic toggle="yes">P</italic>&#8201;=&#8201;0.54, I<sup>2</sup>&#8201;=&#8201;0%), Supplemental Figure S9A.</p></sec><sec id="Sec16"><title>Score on role Function-Restrictive domain of MSQ at 12 weeks</title><p id="Par33">A total of 3 studies reported score on role function-restrictive domain of migraine specific quality of life questionnaire (MSQ) at 12 weeks as an outcome. Analysis included data on different doses of the drug mentioned in each of the studies. A significant difference between atogepant and placebo group was seen (MD: 10.06, 95% CI [9.48, 10.63], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;78%), Supplemental Figure S10. Excluding data from Ailani et al. 2021, reduced the heterogeneity from 78 to 0%, Supplemental Figure S10A.</p><p id="Par34">A subgroup analysis was also performed for this outcome based on different doses of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained significant and no change in heterogeneity (I&#178; remained 78% after subgrouping) was seen (MD: 10.06, 95% CI [9.48, 10.63], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;78%), Supplemental Figure S10B. Subgroup analysis on type of migraine revealed similar results (MD: 10.06, 95% CI [9.48, 10.63], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;78%), Supplemental Figure S10C.</p></sec><sec id="Sec17"><title>Performance score of daily activities domain of AIM-D at 12 weeks</title><p id="Par35">A total of 3 studies reported the outcome performance score of daily activities domain of activity impairment in migraine diary (AIM-D) at 12 weeks. Analysis included different dosages of the medication listed in each of the studies. A significant difference between atogepant and placebo group was seen (MD: &#8722;2.98, 95% CI [&#8722;3.93, &#8722;2.03], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Figure S11. After excluding data from Ailani et al. 2021, the heterogeneity decreased from 99 to 0%, Supplemental Figure S11A.</p><p id="Par36">Subgroup analysis on different doses of atogepant was performed. The results remained significant and no change in heterogeneity (I&#178; remained 99% after subgrouping) was seen (MD: &#8722;2.98, 95% CI [&#8722;3.93, &#8722;2.03], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Figure S11B. Similar results were found upon performing subgroup analysis based on type of migraine (MD: &#8722;2.98, 95% CI [&#8722;3.93, &#8722;2.03], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Figure S11C.</p></sec><sec id="Sec18"><title>Physical impairment score domain of AIM-D at 12 weeks</title><p id="Par37">Three studies reported the outcome score on physical impairment score domain of AIM-D at 12 weeks. Data analyzed included different doses mentioned in each of the studies. Analysis revealed a significant difference between atogepant and placebo group (MD: &#8722;2.29, 95% CI [&#8722;2.97, &#8722;1.60], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Figure S12. Data exclusion from Ailani et al. 2021, reduced the heterogeneity from 99 to 0%, Supplemental Fig. 12A.</p><p id="Par38">Subgroup analysis was done based on different doses of atogepant including 10 mg, 30 mg, and 60 mg once daily, and 30 mg and 60 mg twice daily. The results remained significant and no change in heterogeneity (I&#178; remained 99% after subgrouping) was seen (MD: &#8722;2.29, 95% CI [&#8722;2.97, &#8722;1.60], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Fig. 12B. Similar results were yielded upon subgroup analysis based on type of migraine (MD: &#8722;2.29, 95% CI [&#8722;2.97, &#8722;1.60], <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, I<sup>2</sup>&#8201;=&#8201;99%), Supplemental Fig. 12C.</p></sec></sec></sec><sec id="Sec19"><title>Discussion</title><p id="Par39">In this updated meta-analysis, we comprehensively compared the efficacy and safety of atogepant with placebo or standard care in management of migraine at dose 10 mg, 30 mg, 60 mg. Data was included from 6 RCTs comprising a total of 4052 participants, with 2867 in the atogepant group and 1185 in the placebo or standard treatment group.</p><p id="Par40">Atogepant is part of the CGRP receptor antagonist drug class and is among the latest prophylactic management options for migraine. The neuropeptide CGRP plays a crucial role in the pathogenesis of migraine by activation of meningeal nociceptors and peripheral/central sensitization which leads to headaches [<xref ref-type="bibr" rid="CR24">24</xref>]. Studies have shown that CGRP antagonists are significantly efficacious and have a better safety profile than other treatment options for migraine [<xref ref-type="bibr" rid="CR25">25</xref>]. The American Headache Society (AHS) and European Federation of Neurological Societies (EFNS) recommend a broad range of pharmacological treatment options for management of migraine, which include NSAIDs, triptans, beta blockers, antiepileptic drugs, and CGRP receptor antagonists [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Moreover, in adults who have failed to respond to at least three other migraine prevention drugs or have had safety concerns with those drugs, the 2024 National Institute for Health and Care Excellence (NICE) guidelines from the UK recommends considering atogepant for migraine prophylaxis [<xref ref-type="bibr" rid="CR28">28</xref>]. </p><p id="Par41">The results of the current study showed that atogepant significantly reduced the MMD at 12 weeks compared to placebo or standard treatment. All the trials included in this study were consistent in showing this improvement and the findings support the conclusions of previous meta-analyses [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. The efficacy of atogepant is further evidenced by the significant improvement in terms of reduced MHD at 12 weeks, reduction in MMD by more than or equal to 50%, and a significant reduction in days requiring use of medication for acute episodes of migraine at 12 weeks. These conclusions were consistent with findings of Raja et al., 2024 and Alrasheed et al., 2024 [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Included trials even though suggested that atogepant is effective at all doses, findings of Lipton et al., 2024 suggested that patients who were started on higher doses of atogepant, 60 mg, showed an improved initial response and had a better overall long-term benefit. This study also stated that patients who had better initial improvement, at any dose, experienced long-lasting benefits throughout the course of treatment [<xref ref-type="bibr" rid="CR31">31</xref>]. </p><p id="Par42">A meta-analysis by Lattanzi et al., 2022, evaluated efficacy of atogepant in prevention of episodic migraine using data from two trials [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The results from this study were consistent with findings of our study, however, Lattanzi et al., 2022, analyzed data in patient with just episodic migraine, whereas the current study included data from patients having chronic migraine as well, which is essential to include due to its severe and persistent course [<xref ref-type="bibr" rid="CR32">32</xref>]. </p><p id="Par43">It is essential to assess the safety profile in addition to a drug&#8217;s efficacy in order for it to be used widely. Patients using atogepant reported certain treatment-emergent adverse events (TEAEs) which included constipation, upper respiratory tract infections, nausea, nasopharyngitis, fatigueness, reduced appetite among others. Results from Alrasheed et al., 2024 and Lattanzi et al., 2022 showed no significant difference in terms of side effects when comparing atogepant and placebo. Our study, however, showed a significantly higher risk of TEAEs, particularly gastrointestinal (GI) side effects like constipation and nausea, in the treatment group as compared to placebo. This highlights that although individual RCTs may show insignificance in terms of side effects, pooling data from other studies yields a clear and comprehensive analysis of these outcomes. Our findings were consistent with Raja et al., 2024, Amin et al., 2025, and Huo et al., 2024 [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. This significant increase in GI side effects can be attributed to blockade of CGRP receptors in the GI system [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Moreover, CGRP receptor antagonists have also been shown to act on AMY1 receptors which can further provide a basis for its GI side effects [<xref ref-type="bibr" rid="CR36">36</xref>]. </p><p id="Par44">Current guidelines provided by the U.S. Food and Drug Administration (FDA) recommends atogepant dosages 10, 30, and 60 mg for episodic migraine and 60 mg for chronic migraine [<xref ref-type="bibr" rid="CR37">37</xref>]. This study shows similar efficacy of atogepant at lower and higher dosages, however, literature suggests higher risk of side effects at higher dosage. These findings should be investigated further to develop public health strategies to better identify accurate dosing for select patients in order to keep minimal dosage to maintain similar effect while limiting adverse events.</p><p id="Par45">Our study provides a comprehensive analysis of atogepant&#8217;s efficacy and safety profile by including several RCTs providing a large sample size and assessing multiple outcomes. Moreover, this study examines the effectiveness at different doses of the drug providing an insight into the dose-response relationship, essential for exploring how tailored dosages can help prepare an individualized regimen for patients with different baselines. Furthermore, this study includes patients with episodic migraine as well as chronic migraine which helps provide a robust conclusion on the effectiveness of the drug across a spectrum of severity of migraine. In contrast, our study was not void of limitations. Some of the outcomes showed high heterogeneity and attempts were made to reduce it by excluding data from certain studies and performing subgroup analysis. The high heterogeneity due to inclusion of certain studies can be explained by unique dosage regimens, exclusion criteria, and regional diversity. Secondly, the patient demographic assessed in this study was mainly focused on women from the Western world which may affect the generalizability of the results, thus further studies are required in different regions of the world to provide a more enhanced comparison. Thirdly, the treatment course of trials was limited to 12-week response which limits the details on safety and efficacy of the drug, thus, further studies with longer treatment periods are required to assess long-term (side) effects of atogepant.</p></sec><sec id="Sec20"><title>Conclusion</title><p id="Par46">In conclusion, this study shows that atogepant is a highly efficacious medication in prevention of migraine, however, its questionable safety profile emphasizes the importance of careful dosage selection while prescribing the drug in patients with different characteristics. Current studies are focused on limited patient characteristics and have a small follow-up period, thus, future studies should focus on including a diverse study population with different baseline characteristics and socioeconomic backgrounds along with a longer follow-up period to determine the long-term (side) effects of the drug.</p></sec><sec id="Sec21" sec-type="supplementary-material"><title>Supplementary information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="12883_2025_4394_MOESM1_ESM.docx" position="float" orientation="portrait"><label>ESM 1</label><caption><p>(DOCX 3.44 MB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>None.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>N.K.L, P.B, R.L: Conceptualization, Manuscript Writing and EditingA.M.S, S.B, G.U.A: Extraction, Analysis, Manuscript Writing and EditingR.Z, V.F.S, A.H, S.A: Figures, Manuscript Writing and EditingM.H.B, M.A, M.T: Tables, Manuscript Writing and Editing.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors received no extramural funding for the study.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The dataset supporting the conclusions of this article are included in this article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par47">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par48">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Migraine | National Institute of Neurological Disorders and Stroke. Accessed March 24. 2025. <ext-link ext-link-type="uri" xlink:href="https://www.ninds.nih.gov/health-information/disorders/migraine">https://www.ninds.nih.gov/health-information/disorders/migraine</ext-link></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amiri</surname><given-names>P</given-names></name><name name-style="western"><surname>Kazeminasab</surname><given-names>S</given-names></name><name name-style="western"><surname>Nejadghaderi</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Migraine: A review on its history, global epidemiology, risk factors, and comorbidities</article-title><source>Front Neurol</source><year>2022</year><volume>12</volume><fpage>800605</fpage><pub-id pub-id-type="doi">10.3389/FNEUR.2021.800605</pub-id><pub-id pub-id-type="pmid">35281991</pub-id><pub-id pub-id-type="pmcid">PMC8904749</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Amiri P, Kazeminasab S, Nejadghaderi SA, et al. Migraine: A review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol. 2022;12:800605. 10.3389/FNEUR.2021.800605.<pub-id pub-id-type="pmid">35281991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2021.800605</pub-id><pub-id pub-id-type="pmcid">PMC8904749</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Migraine - Symptoms and causes - Mayo Clinic. Accessed March 24. 2025. <ext-link ext-link-type="uri" xlink:href="https://www.mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/syc-20360201">https://www.mayoclinic.org/diseases-conditions/migraine-headache/symptoms-causes/syc-20360201</ext-link></mixed-citation></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name><name name-style="western"><surname>Buse</surname><given-names>DC</given-names></name><name name-style="western"><surname>Nahas</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Risk factors for migraine disease progression: a narrative review for a patient-centered approach</article-title><source>J Neurol</source><year>2023</year><volume>270</volume><issue>12</issue><fpage>5692</fpage><pub-id pub-id-type="doi">10.1007/S00415-023-11880-2</pub-id><pub-id pub-id-type="pmid">37615752</pub-id><pub-id pub-id-type="pmcid">PMC10632231</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Lipton RB, Buse DC, Nahas SJ, et al. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023;270(12):5692. 10.1007/S00415-023-11880-2.<pub-id pub-id-type="pmid">37615752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-023-11880-2</pub-id><pub-id pub-id-type="pmcid">PMC10632231</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steiner</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Stovner</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>R</given-names></name><name name-style="western"><surname>Uluduz</surname><given-names>D</given-names></name><name name-style="western"><surname>Katsarava</surname><given-names>Z</given-names></name></person-group><article-title>Migraine remains second among the world&#8217;s causes of disability, and first among young women: findings from GBD2019</article-title><source>J Headache Pain</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/S10194-020-01208-0</pub-id><pub-id pub-id-type="pmid">33267788</pub-id><pub-id pub-id-type="pmcid">PMC7708887</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world&#8217;s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. 10.1186/S10194-020-01208-0.<pub-id pub-id-type="pmid">33267788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-020-01208-0</pub-id><pub-id pub-id-type="pmcid">PMC7708887</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andreou</surname><given-names>AP</given-names></name><name name-style="western"><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Mechanisms of migraine as a chronic evolutive condition</article-title><source>J Headache Pain</source><year>2019</year><volume>20</volume><issue>1</issue><fpage>117</fpage><pub-id pub-id-type="doi">10.1186/S10194-019-1066-0</pub-id><pub-id pub-id-type="pmid">31870279</pub-id><pub-id pub-id-type="pmcid">PMC6929435</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1):117. 10.1186/S10194-019-1066-0.<pub-id pub-id-type="pmid">31870279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-019-1066-0</pub-id><pub-id pub-id-type="pmcid">PMC6929435</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noseda</surname><given-names>R</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>R</given-names></name></person-group><article-title>Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain</article-title><source>Pain</source><year>2013</year><volume>154</volume><issue>SUPPL 1</issue><fpage>S44</fpage><lpage>S53</lpage><pub-id pub-id-type="doi">10.1016/J.PAIN.2013.07.021</pub-id><pub-id pub-id-type="pmid">23891892</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Noseda R, Burstein R. Migraine pathophysiology: Anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain. 2013;154(SUPPL 1):S44&#8211;53. 10.1016/J.PAIN.2013.07.021.<pub-id pub-id-type="pmid">23891892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pain.2013.07.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>The CGRP pathway in migraine as a viable target for therapies</article-title><source>Headache</source><year>2018</year><volume>58</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">29697153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/head.13305</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58:33&#8211;47 10.1111/HEAD.13305.<pub-id pub-id-type="pmid">29697153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/head.13305</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>S</given-names></name><name name-style="western"><surname>Aldous</surname><given-names>L</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>B</given-names></name></person-group><article-title>Calcitonin gene-related peptide&#8211;targeted therapies for migraine</article-title><source>Aust Prescr</source><year>2025</year><volume>48</volume><issue>2</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.18773/AUSTPRESCR.2025.017</pub-id><pub-id pub-id-type="pmid">40343132</pub-id><pub-id pub-id-type="pmcid">PMC12055492</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Barnes S, Aldous L, Jenkins B. Calcitonin gene-related peptide&#8211;targeted therapies for migraine. Aust Prescr. 2025;48(2):40. 10.18773/AUSTPRESCR.2025.017.<pub-id pub-id-type="pmid">40343132</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18773/austprescr.2025.017</pub-id><pub-id pub-id-type="pmcid">PMC12055492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charles</surname><given-names>A</given-names></name></person-group><article-title>The pathophysiology of migraine: implications for clinical management</article-title><source>Lancet Neurol</source><year>2018</year><volume>17</volume><issue>2</issue><fpage>174</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(17)30435-0/ASSET/01FD4EE0-4025-4A53-BEB6</pub-id><pub-id pub-id-type="pmid">29229375</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174&#8211;82. 10.1016/S1474-4422(17)30435-0/ASSET/01FD4EE0-4025-4A53-BEB6.<pub-id pub-id-type="pmid">29229375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30435-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giraldo</surname><given-names>JP</given-names></name><name name-style="western"><surname>Zarifkar</surname><given-names>P</given-names></name><name name-style="western"><surname>Migraine</surname></name><name name-style="western"><surname>Headache</surname></name></person-group><article-title>Encyclopedia of child and adolescent health</article-title><source>First Ed</source><year>2024</year><volume>1</volume><fpage>151</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-818872-9.00149-7</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Giraldo JP, Zarifkar P, Migraine, Headache. Encyclopedia of child and adolescent health. First Ed. 2024;1:151&#8211;67. 10.1016/B978-0-12-818872-9.00149-7.</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jenkins</surname><given-names>B</given-names></name></person-group><article-title>Migraine management</article-title><source>Aust Prescr</source><year>2020</year><volume>43</volume><issue>5</issue><fpage>148</fpage><pub-id pub-id-type="doi">10.18773/AUSTPRESCR.2020.047</pub-id><pub-id pub-id-type="pmid">33093740</pub-id><pub-id pub-id-type="pmcid">PMC7572189</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Jenkins B. Migraine management. Aust Prescr. 2020;43(5):148. 10.18773/AUSTPRESCR.2020.047.<pub-id pub-id-type="pmid">33093740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18773/austprescr.2020.047</pub-id><pub-id pub-id-type="pmcid">PMC7572189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ailani</surname><given-names>J</given-names></name><name name-style="western"><surname>Lalla</surname><given-names>A</given-names></name><name name-style="western"><surname>Halker Singh</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene&#8211;related peptide monoclonal antibodies</article-title><source>Cephalalgia</source><year>2024</year><volume>44</volume><issue>11</issue><fpage>3331024241299377</fpage><pub-id pub-id-type="doi">10.1177/03331024241299377/SUPPL_FILE/SJ-DOCX-1-CEP-10.1177_03331024241299377.DOCX</pub-id><pub-id pub-id-type="pmid">39558612</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Ailani J, Lalla A, Halker Singh RB, et al. Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene&#8211;related peptide monoclonal antibodies. Cephalalgia. 2024;44(11):3331024241299377. 10.1177/03331024241299377/SUPPL_FILE/SJ-DOCX-1-CEP-10.1177_03331024241299377.DOCX.<pub-id pub-id-type="pmid">39558612</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/03331024241299377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis</article-title><source>J Headache Pain</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1186/S10194-024-01822-2/TABLES/2</pub-id><pub-id pub-id-type="pmid">39030528</pub-id><pub-id pub-id-type="pmcid">PMC11264921</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hou M, Luo X, He S, et al. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2024;25(1):1&#8211;16. 10.1186/S10194-024-01822-2/TABLES/2.<pub-id pub-id-type="pmid">39030528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-024-01822-2</pub-id><pub-id pub-id-type="pmcid">PMC11264921</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/BMJ.N71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. 10.1136/BMJ.N71.<pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shea</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>BC</given-names></name><name name-style="western"><surname>Wells</surname><given-names>G</given-names></name><etal/></person-group><article-title>AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both</article-title><source>BMJ</source><year>2017</year><volume>358</volume><fpage>4008</fpage><pub-id pub-id-type="doi">10.1136/BMJ.J4008</pub-id><pub-id pub-id-type="pmcid">PMC5833365</pub-id><pub-id pub-id-type="pmid">28935701</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:4008. 10.1136/BMJ.J4008.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.j4008</pub-id><pub-id pub-id-type="pmcid">PMC5833365</pub-id><pub-id pub-id-type="pmid">28935701</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins</surname><given-names>JPT</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name><name name-style="western"><surname>G&#248;tzsche</surname><given-names>PC</given-names></name><etal/></person-group><article-title>The Cochrane Collaboration&#8217;s tool for assessing risk of bias in randomised trials</article-title><source>BMJ</source><year>2011</year><volume>343</volume><issue>7829</issue><fpage>d5928</fpage><pub-id pub-id-type="doi">10.1136/BMJ.D5928</pub-id><pub-id pub-id-type="pmid">22008217</pub-id><pub-id pub-id-type="pmcid">PMC3196245</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Higgins JPT, Altman DG, G&#248;tzsche PC, et al. The Cochrane Collaboration&#8217;s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(7829):d5928. 10.1136/BMJ.D5928.<pub-id pub-id-type="pmid">22008217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.d5928</pub-id><pub-id pub-id-type="pmcid">PMC3196245</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tassorelli</surname><given-names>C</given-names></name><name name-style="western"><surname>Nagy</surname><given-names>K</given-names></name><name name-style="western"><surname>Pozo-Rosich</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safety and efficacy of Atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial</article-title><source>Lancet Neurol</source><year>2024</year><volume>23</volume><issue>4</issue><fpage>382</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(24)00025-5</pub-id><pub-id pub-id-type="pmid">38364831</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Tassorelli C, Nagy K, Pozo-Rosich P, et al. Safety and efficacy of Atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024;23(4):382&#8211;92. 10.1016/S1474-4422(24)00025-5.<pub-id pub-id-type="pmid">38364831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00025-5</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695&#8211;706.&#160;10.1056/NEJMOA2035908/SUPPL_FILE/NEJMOA2035908_DATA-SHARING.PDF<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035908</pub-id><pub-id pub-id-type="pmid">34407343</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozo-Rosich</surname><given-names>P</given-names></name><name name-style="western"><surname>Ailani</surname><given-names>J</given-names></name><name name-style="western"><surname>Ashina</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial</article-title><source>Lancet</source><year>2023</year><volume>402</volume><issue>10404</issue><fpage>775</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(23)01049-8</pub-id><pub-id pub-id-type="pmid">37516125</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10404):775&#8211;85. 10.1016/S0140-6736(23)01049-8.<pub-id pub-id-type="pmid">37516125</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(23)01049-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Dodick</surname><given-names>DW</given-names></name><name name-style="western"><surname>Ailani</surname><given-names>J</given-names></name><etal/></person-group><article-title>Safety, tolerability, and efficacy of orally administered Atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial</article-title><source>Lancet Neurol</source><year>2020</year><volume>19</volume><issue>9</issue><fpage>727</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30234-9</pub-id><pub-id pub-id-type="pmid">32822633</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered Atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727&#8211;37. 10.1016/S1474-4422(20)30234-9.<pub-id pub-id-type="pmid">32822633</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(20)30234-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>DI</given-names></name><name name-style="western"><surname>Holle-Lee</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial</article-title><source>Neurology</source><year>2024</year><volume>103</volume><issue>2</issue><fpage>e209584</fpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000209584</pub-id><pub-id pub-id-type="pmid">38924724</pub-id><pub-id pub-id-type="pmcid">PMC11254449</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial. Neurology. 2024;103(2):e209584. 10.1212/WNL.0000000000209584.<pub-id pub-id-type="pmid">38924724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000209584</pub-id><pub-id pub-id-type="pmcid">PMC11254449</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Study Results | Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60&#160;mg Daily for the Prevention of Migraine in Participants With Episodic Migraine | ClinicalTrials.gov. Accessed March 24. 2025. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/study/NCT03700320?tab=results">https://clinicaltrials.gov/study/NCT03700320?tab=results</ext-link></mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>D</given-names></name><name name-style="western"><surname>Labastida-Ramirez</surname><given-names>A</given-names></name><name name-style="western"><surname>MaassenVanDenBrink</surname><given-names>A</given-names></name></person-group><article-title>Current Understanding of meningeal and cerebral vascular function underlying migraine headache</article-title><source>Cephalalgia</source><year>2019</year><volume>39</volume><issue>13</issue><fpage>1606</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1177/0333102418771350</pub-id><pub-id pub-id-type="pmid">29929378</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Levy D, Labastida-Ramirez A, MaassenVanDenBrink A. Current Understanding of meningeal and cerebral vascular function underlying migraine headache. Cephalalgia. 2019;39(13):1606&#8211;22. 10.1177/0333102418771350.<pub-id pub-id-type="pmid">29929378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0333102418771350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>F</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>H</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>SD</given-names></name></person-group><article-title>Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale</article-title><source>BioDrugs</source><year>2022</year><volume>36</volume><fpage>341</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1007/S40259-022-00530-0</pub-id><pub-id pub-id-type="pmid">35476215</pub-id><pub-id pub-id-type="pmcid">PMC9043885</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022;36:341&#8211;58. 10.1007/S40259-022-00530-0.<pub-id pub-id-type="pmid">35476215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40259-022-00530-0</pub-id><pub-id pub-id-type="pmcid">PMC9043885</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charles</surname><given-names>AC</given-names></name><name name-style="western"><surname>Digre</surname><given-names>KB</given-names></name><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hershey</surname><given-names>A</given-names></name></person-group><article-title>Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update</article-title><source>Headache</source><year>2024</year><volume>64</volume><issue>4</issue><fpage>333</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/HEAD.14692</pub-id><pub-id pub-id-type="pmid">38466028</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache. 2024;64(4):333&#8211;41. 10.1111/HEAD.14692.<pub-id pub-id-type="pmid">38466028</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/head.14692</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evers</surname><given-names>S</given-names></name><name name-style="western"><surname>&#193;fra</surname><given-names>J</given-names></name><name name-style="western"><surname>Frese</surname><given-names>A</given-names></name><etal/></person-group><article-title>EFNS guideline on the drug treatment of migraine&#8211;revised report of an EFNS task force</article-title><source>Eur J Neurol</source><year>2009</year><volume>16</volume><issue>9</issue><fpage>968</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/J.1468-1331.2009.02748.X</pub-id><pub-id pub-id-type="pmid">19708964</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Evers S, &#193;fra J, Frese A, et al. EFNS guideline on the drug treatment of migraine&#8211;revised report of an EFNS task force. Eur J Neurol. 2009;16(9):968&#8211;81. 10.1111/J.1468-1331.2009.02748.X.<pub-id pub-id-type="pmid">19708964</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1468-1331.2009.02748.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Overview. | Atogepant for preventing migraine | Guidance | NICE. Accessed March 24, 2025. <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/ta973">https://www.nice.org.uk/guidance/ta973</ext-link></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alrasheed</surname><given-names>AS</given-names></name><name name-style="western"><surname>Almaqboul</surname><given-names>TM</given-names></name><name name-style="western"><surname>Alshamrani</surname><given-names>RA</given-names></name><name name-style="western"><surname>AlMohish</surname><given-names>NM</given-names></name><name name-style="western"><surname>Alabdali</surname><given-names>MM</given-names></name></person-group><article-title>Safety and efficacy of Atogepant for the preventive treatment of migraines in adults: A systematic review and Meta-Analysis</article-title><source>J Clin Med 2024</source><year>2024</year><volume>13</volume><issue>22</issue><fpage>6713</fpage><pub-id pub-id-type="doi">10.3390/JCM13226713</pub-id><pub-id pub-id-type="pmcid">PMC11595008</pub-id><pub-id pub-id-type="pmid">39597856</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Alrasheed AS, Almaqboul TM, Alshamrani RA, AlMohish NM, Alabdali MM. Safety and efficacy of Atogepant for the preventive treatment of migraines in adults: A systematic review and Meta-Analysis. J Clin Med 2024. 2024;13(22):6713. 10.3390/JCM13226713.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm13226713</pub-id><pub-id pub-id-type="pmcid">PMC11595008</pub-id><pub-id pub-id-type="pmid">39597856</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raja</surname><given-names>A</given-names></name><name name-style="western"><surname>Asim</surname><given-names>R</given-names></name><name name-style="western"><surname>Shuja</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults</article-title><source>Front Neurol</source><year>2024</year><volume>15</volume><fpage>1468961</fpage><pub-id pub-id-type="doi">10.3389/FNEUR.2024.1468961/BIBTEX</pub-id><pub-id pub-id-type="pmid">39399876</pub-id><pub-id pub-id-type="pmcid">PMC11466836</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Raja A, Asim R, Shuja MH, et al. Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults. Front Neurol. 2024;15:1468961. 10.3389/FNEUR.2024.1468961/BIBTEX.<pub-id pub-id-type="pmid">39399876</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2024.1468961</pub-id><pub-id pub-id-type="pmcid">PMC11466836</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipton</surname><given-names>RB</given-names></name><name name-style="western"><surname>Nahas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Pozo-Rosich</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sustained response to Atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial</article-title><source>J Headache Pain</source><year>2024</year><volume>25</volume><issue>1</issue><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1186/S10194-024-01783-6/FIGURES/7</pub-id><pub-id pub-id-type="pmid">38773375</pub-id><pub-id pub-id-type="pmcid">PMC11107063</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Lipton RB, Nahas SJ, Pozo-Rosich P, et al. Sustained response to Atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial. J Headache Pain. 2024;25(1):1&#8211;11. 10.1186/S10194-024-01783-6/FIGURES/7.<pub-id pub-id-type="pmid">38773375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-024-01783-6</pub-id><pub-id pub-id-type="pmcid">PMC11107063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lattanzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Trinka</surname><given-names>E</given-names></name><name name-style="western"><surname>Altamura</surname><given-names>C</given-names></name><etal/></person-group><article-title>Atogepant for the prevention of episodic migraine in adults: A systematic review and Meta-Analysis of efficacy and safety</article-title><source>Neurol Ther</source><year>2022</year><volume>11</volume><issue>3</issue><fpage>1235</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/S40120-022-00370-8</pub-id><pub-id pub-id-type="pmid">35705886</pub-id><pub-id pub-id-type="pmcid">PMC9338214</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lattanzi S, Trinka E, Altamura C, et al. Atogepant for the prevention of episodic migraine in adults: A systematic review and Meta-Analysis of efficacy and safety. Neurol Ther. 2022;11(3):1235&#8211;52. 10.1007/S40120-022-00370-8.<pub-id pub-id-type="pmid">35705886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40120-022-00370-8</pub-id><pub-id pub-id-type="pmcid">PMC9338214</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amin</surname><given-names>AM</given-names></name><name name-style="western"><surname>Abbas</surname><given-names>A</given-names></name><name name-style="western"><surname>Amer</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Does Atogepant offer a safe and efficacious option for episodic migraine prophylaxis?? A systematic review and Meta-analysis</article-title><source>Headache Pain Res</source><year>2025</year><volume>26</volume><issue>1</issue><fpage>21</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.62087/HPR.2024.0030</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Amin AM, Abbas A, Amer SA, et al. Does Atogepant offer a safe and efficacious option for episodic migraine prophylaxis?? A systematic review and Meta-analysis. Headache Pain Res. 2025;26(1):21&#8211;37. 10.62087/HPR.2024.0030.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haanes</surname><given-names>KA</given-names></name><name name-style="western"><surname>Edvinsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Sams</surname><given-names>A</given-names></name></person-group><article-title>Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies</article-title><source>J Headache Pain</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/S10194-020-01097-3</pub-id><pub-id pub-id-type="pmid">32178623</pub-id><pub-id pub-id-type="pmcid">PMC7077114</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Haanes KA, Edvinsson L, Sams A. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies. J Headache Pain. 2020;21(1):26. 10.1186/S10194-020-01097-3.<pub-id pub-id-type="pmid">32178623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s10194-020-01097-3</pub-id><pub-id pub-id-type="pmcid">PMC7077114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ailani</surname><given-names>J</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>EA</given-names></name><name name-style="western"><surname>Mathew</surname><given-names>PG</given-names></name><etal/></person-group><article-title>Role of calcitonin Gene-Related peptide on the Gastrointestinal symptoms of Migraine-Clinical considerations: A narrative review</article-title><source>Neurology</source><year>2022</year><volume>99</volume><issue>19</issue><fpage>841</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000201332</pub-id><pub-id pub-id-type="pmid">36127137</pub-id><pub-id pub-id-type="pmcid">PMC9651456</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ailani J, Kaiser EA, Mathew PG, et al. Role of calcitonin Gene-Related peptide on the Gastrointestinal symptoms of Migraine-Clinical considerations: A narrative review. Neurology. 2022;99(19):841&#8211;53. 10.1212/WNL.0000000000201332.<pub-id pub-id-type="pmid">36127137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000201332</pub-id><pub-id pub-id-type="pmcid">PMC9651456</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreno-Ajona</surname><given-names>D</given-names></name><name name-style="western"><surname>Gosalia</surname><given-names>H</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>J</given-names></name><name name-style="western"><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>Amylin and the amylin receptors in migraine: Is there another pathway to target?</article-title><source>Cephalalgia</source><year>2025</year><volume>45</volume><issue>5</issue><fpage>3331024251340066</fpage><pub-id pub-id-type="doi">10.1177/03331024251340066</pub-id><pub-id pub-id-type="pmid">40388703</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Moreno-Ajona D, Gosalia H, Hoffmann J, Goadsby PJ. Amylin and the amylin receptors in migraine: Is there another pathway to target? Cephalalgia. 2025;45(5):3331024251340066. 10.1177/03331024251340066.<pub-id pub-id-type="pmid">40388703</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/03331024251340066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">fda cder. HIGHLIGHTS OF PRESCRIBING INFORMATION. Accessed August 5, 2025. <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</ext-link></mixed-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>